Contribute Try STAT+ Today

Everyone loves a winner, but who are they? Let us help you figure it out. Each Friday, we will provide a quick rundown of individuals or companies that accomplished something worth noting. But to be fair, we will also point out those who, well, had a rough time. And if you have a nomination, send us a note. We would not want anyone to feel left out, even the losers.

Winners

Pharma CEOs: Amid political upheaval, pricing uncertainty, and public backlash, it still pays to be a pharma chief. AstraZeneca CEO Pascal Soriot made $16.3 million in total compensation last year, a 68 percent jump over his 2015 haul. Richard Gonzalez, CEO of AbbVie, brought in $21 million, while the leaders of Novartis and Roche each made about $12 million. In the next few weeks, we’ll learn how much the CEOs of Regeneron, Johnson & Johnson, and Allergan took home in 2016, too. Expect a great many zeros.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.